NEW! Health Care M & A Blog

E-HEALTH

Acquirer

Target

Price

Dell, Inc.

Perot Systems Corporation

$3.9 billion

What’s Hot

To increase revenue from providing services to customers and offset its stagnant personal computer business, Dell is buying Perot Systems for $30.00 per share, or $3.9 billion. Perot Systems Corp. provides IT services and business solutions worldwide, and derives half its revenue from its health care business.

PHARMACEUTICALS

Acquirer

Target

Price

Warner Chilcott, Ltd.

P&G global pharmaceuticals business

$3.1 billion

What’s Hot

In a transaction that should increase its sales by over two times, Warner Chilcott is paying $3.1 billion, or 1.4x revenue, to acquire Procter and Gamble’s global pharmaceutical business. Procter and Gamble had been seeking to exit the prescription drug business.

MEDICAL DEVICES

Acquirer

Target

Price

Danaher Corporation

Life sciences instrumentation business

$1.1 million

What’s Hot

In a deal valued at $1.1 billion, MDS, Inc. and Life Technologies Corp. are selling their interests in the Applied Biosystems/MDS Sciex joint venture, a mass spectrometry business, and Molecular Devices Corp., a bioresearch and analytical instrumentation business, to Danaher Corp.

LONG-TERM CARE

Acquirer

Target

Price

Blackstone Real Estate Advisors

148-facility portfolio

$1.1 billion

What’s Hot

Blackstone Real Estate Advisors is partnering with Emeritus Senior Living to acquire a portfolio of 148 senior living facilities from Sunwest Management for approximately $1.1 billion in equity and debt. Sunwest is currently reorganizing. If the deal goes through, Emeritus will manage the facilities.

BIOTECHNOLOGY

Acquirer

Target

Price

Roche Holding AG

CNS drug development deal

$968.0 million

What’s Hot

In a development deal that is worth up to $968.0 million in upfront and milestone payments, New Jersey-based PTC Therapeutics is forging an exclusive research collaboration and licensing agreement with Roche Holding to develop orally bioavailable small molecules focusing on CNS disease targets. The deal also provides for an additional four targets, which could raise the value of the entire collaboration to $1.9 billion.